key: cord-1048439-ybgrzzzm
authors: Batiha, Gaber El-Saber; Al-Gareeb, Dr. Ali I.; Qusti, Safaa; Alshammari, Eida M.; Rotimi, Damilare; Adeyemi, Oluyomi Stephen; Al-kuraishy, Hayder M.
title: Common NLRP3 inflammasome inhibitors and Covid-19: Divide and Conquer
date: 2021-12-18
journal: Sci Afr
DOI: 10.1016/j.sciaf.2021.e01084
sha: 1d58835e09ccb52857c5eae87fa2e7ce80d167ea
doc_id: 1048439
cord_uid: ybgrzzzm

Severe SARS-CoV-2 infection causes systemic inflammation, cytokine storm and hypercytokinemia due to activation the release of pro-inflammatory cytokines that have been associated with case-fatality rate. The immune overreaction and cytokine storm in the infection caused by SARS-CoV-2 may be linked to NLRP3 inflammasome activation which has supreme importance in human innate immune response mainly against viral infections. In SARS-CoV-2 infection, NLRP3 inflammasome activation results in the stimulation and synthesis of natural killer cells (NKs), NFκB, and interferon gamma (INF-γ), while inhibiting IL-33 expression. Various efforts have identified selective inhibitors of NLRP3 inflammasome. To achieve this, studies are exploring the screening of natural compounds and/or repurposing of clinical drugs to identify potential NLRP3 inhibitors. NLRP3 inflammasome inhibitors are expected to suppress exaggerated immune reaction and cytokine storm induced-organ damage in SARS-CoV-2 infection. Therefore, NLRP3 inflammasome inhibitors could mitigate the immune-overreaction and hypercytokinemia in Covid-19 infection.

The inflammasomes are multi-protein of innate immunity responsible for regulation of proinflammatory response. [1] Inflammasomes enhances proteolytic cleavage and release the proinflammatory cytokines (IL-18, IL-1β) and gasdermin-D which are N-terminal fragment responsible for induction of cytokine release and pyroptosis. [2] In turn, the inflammasomes are activated through cytosolic pattern recognition receptors (PRRs) that are stimulated by pathogenassociated molecular patterns (PAMPs) from microbial pathogen and damage-associated molecular patterns (DAMPs) from host cell damage. The PRRs comprise leucine-rich receptors (NLRs) and nucleotide-binding domain [3, 4] . Activation of inflammasomes receptors activates caspase-1 for proteolytic cleavage of immature pro-inflammatory cytokines. Some inflammasomes are activated independently of caspase-1 pathway, by bacterial lipopolysaccharide through caspase-11 leading to pyroptosis. [5] In brief, activation of NLRP3 inflammasomes by hypoxia, DAMPs and PAMPs lead to proteolytic conversion to produce caspase-1 from of pro-caspase-1 which activates the conversion of pro-IL1β and pro-IL-18 to IL-1β and IL-18 respectively that together induce inflammation. Likewise, caspase-1 activates Gasdermine D leading to pyroptosis. Both pyroptosis and inflammation increase risk of thrombosis and other coagulopathy. (Figure 1 ). [6] These inflammasomes are named conical inflammasomes like NLR1, NLR2, NLR3, and NLR4. [7] NLR1 found in the neurons, while NLR2 and NLR3 are found in the microglia. NLR1 is activated by bacterial toxin and inhibited by Bcl-2. [8] NLR3 is the largest one among other NLRs, and it is regulated by PAMPs and DAMPs. [9] NLR3 is also activated by cholesterol crystals and monosodium urate, thus explaining the role of NLRP3 inflammasome in the origin and development of atherosclerosis and gout. [10, 11] NLRP3 inflammasome is inhibited by dapansutrile and diarylsulfonylurea MCC-950. NLR4 inflammasome is activated by palmitate and inhibited by cyclic adenosine monophosphate (cAMP). [12] During acute infection, PRRs recognize PAMPs and DAMPs, either through toll-like receptors (TLRs) in the membrane or by nod-like receptors (NLRs) within the cytoplasm that activate NLR3 inflammasome in the macrophages. [13] IL-1β and IL-18 are released after NLRP3 inflammasome activation leading to stimulation of natural killer cells (NKs), NFκB, and interferon gamma (INF-γ) secretion with inhibition of IL-33. [14] Activation of NLRP3 inflammasome is regulated by a priming progression that upregulates NLRP3 genes in response to DAMPs and PAMPs through purine sensing receptors. [15] DAMPs and PAMPs activate PRRs like TLRs and nucleotide-binding oligomerization domain-containing protein 2 (NOD2) with subsequent stimulation of NFκB pathway. [16] This priming contributes to macrophage activation and increase the expression of IL1β gene with post-translation modification of NLRP3 inflammasome through modulation of the activation of cell membrane ion channels, lysosome disruption and mitochondrial dysfunction. [17] In addition, activation of NLRP3 inflammasome induces T cells pyroptosis via gasdermin D (GSDMD) dependent-activation of caspase 1, 4, 5. Also, GSDMD provokes IL-1β and IL-18 release. [18] 

Covid-19 also known as Coronavirus disease has become a global challenge and caused by a virus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The SARS-CoV-2 is a single-strand RNA virus with similar features as SARS-CoV-1 and MERS-CoV-1 (Middle East respiratory syndrome-coronavirus 1). [19] The focal targets of the virus in the human host is the angiotensin converting enzyme 2 (ACE2) receptors that is highly expressed in the lung epithelial cells, proximal renal tubules, brain, and heart. The infection of this virus induced an acute host immune response, cytokine storm and inflammatory reaction which leads to acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). [20] The clinical manifestation among Covid-19 patients revealed that around 85% had asymptomatic to mild cases, while severe and critical cases were about 10% and 5% respectively. Severe SARS-CoV-2 infection causes ALI and ARDS with systemic inflammation, cytokine storm, and hypercytokinemia due to activation of the release of pro-inflammatory cytokines IL-1β and IL-6) that associated with case-fatality rate. [21, 22] Wen et al., [23] illustrated that IL-1β producing monocytes are increased with reduction in T cells in early recover phase in severe Covid-19 patients suggesting immune-dysregulations. The immune overreaction and cytokine storm during the infection may be due to activation of NLRP3 inflammasome which have supreme importance in human innate immune response mainly against viral infections. [24] It has been reported that SARS-CoV activates NLRP3 INFs via 3a protein in lipopolysaccharide primed macrophages with subsequent release of IL-1β. [25] Sun et al., [26] reported that downregulation of ACE2 during SARS-CoV infection with elevation of angiotensin II (AngII) might cause AngII-dependent NLRP3 inflammasome activation. In addition, the activated NLRP3 inflammasome drive AngII to cause proliferation of vascular smooth muscle cells and vascular remodeling. [27] Moreover, plasma and bronchoalveolar fluid of patients with MERS-CoV-1 and SARS-CoV infections have higher IL-1β concentrations which correlated with development of ALI, ARDS, and poor clinical outcomes. [28] Similarly, high IL-1β level is associated with ALI in influenza infection. [29] Therefore, IL-1β receptor antagonists may attenuate respiratory viral infection induced-ALI since NLRP3 inflammasome and IL-1β are involved in the pathogenesis of viral complications. [30] The interaction between the ACE2 receptor and SARS-CoV-2 lead to direct activation of NLRP3 inflammasome or indirectly through DAMPs and PAMPs from injured and apoptotic type II alveolar cells that activate lung macrophages. [31] Besides, SARS-CoV-2 activate lung macrophage to release IL-1β and TNF-α that organize a feed-back loop for NLRP3 inflammasome activation and immune cell recruitments through generation of DAMPs and PAMPs. [32] Up to date, SARS-CoV-2 infection may induce local pulmonary inflammatory microenvironment by inducing TNF-α and IL-1β, release that mutually participate into pulmonary vascular endothelial injury and development of pulmonary edema. [33] TNF-α and IL-1β activate the release of IL-6 from NLRP3 inflammasome which causes disruption of alveolar-capillary unit, with subsequent respiratory failure and systemic inflammatory storm. Cell membrane TNF-α in Covid-19 patients activates TLR4 that increase the sensitivity of NLRP3 inflammasome. [34] Genomic analysis of SARS-CoV, illustrated that ion channel proteins like E protein, open reading frame 3a (ORF3a) and ORF8a required for virulence and replication, act as NLRP3 inflammasome agonist for the release of IL-1β. [35] These ion channel proteins also found in SARS-CoV-2 and participate in the induction of cellular organelle stress, production of free radicals and oxidative stress via NF-κB and caspase-1 activation. ORF8a is involved in SARS-CoV-2 pathogenesis and virulence through a suppression of interferon from virally-infected cells. [36] It has been shown, that memeantine and gliclazide are potent SARS-CoV-2 E protein inhibitors (Figure 2) . [37] Moreover, genetic variation in the host NLRP3 inflammasome may affect the binding with the viral protein of SARS-CoV-2. [38] During SARS-CoV-2 infections, NLRP3 inflammasome have been noted to have a potential interaction myeloid differentiation primary response 88 (MYD88). Activated TLR4 and high IL-1β level stimulate NF-κB through cytoplasmic MYD88 or through caspase-8, which led to IL-1β synthesis and the stimulation of NLRP3 inflammasome. (Figure 3) . [39] During the recovery phase, NLRP3 inflammasome cytokines are decreased with compensatory immunosuppressive phase which is characterized by IL-10 elevation and polarization of anti-inflammatory macrophage (M2). In this phase fibroblasts and platelets are recruited and deposited in the lung extracellular matrix with fibrosis and collagen formation, a hallmark of ARDS. [40] 

Aberrant hyperactivation of NLRP3 inflammasome during SARS-CoV-1, MERS-CoV, SARS-CoV-2 and other respiratory viral infections is associated with ALI and ARDS development due to proinflammatory cytokines release and cytokine storm development. [41] Several studies showed that the inhibitors of NLRP3 inflammasome either naturally or by repurposing of clinically approved drugs. Juliana et al., [42] recently reported that both a natural product parthenolide and synthetic Bay 11-7082 are potent inhibitors of NLRP3 inflammasome ATPase, independent of NF-κB signaling. Similarly, oridonin which is the active ingredient of Rabdosia rubescens has anti-inflammatory effect by inhibiting cysteine 279 of NLRP3 inflammasome, thus making it an effective agent against NLRP3-driven inflammatory disorders. [43] In addition, mefenamic acid and flufenamic acid which are members of the non-steroidal antiinflammatory drugs (NSAID), are non-selective inhibitors of cyclooxygenase enzyme, and they also suppress the activity of NLRP3 inflammasome via inhibition of membrane volume anion chloride channel. [44] Recently, mefenamic acid was observed as an effective therapeutic option against SARS-CoV-2 infection-associated hyperinflammation by inhibiting NLRP3 inflammasome with reduction of viral entry through inhibition of transmembrane protease serine 2 (TMPRSS2). [45] Animal model study by Zhou et al., [46] demonstrated that a low dose of aspirin inhibits endothelial injury through suppression the synthesis and activation of NLRP3 inflammasome. Furthermore, in a multi-center cohort study , aspirin was independently linked with low risk of admission into intensive care unit, mechanical ventilation and mortality in patients with Covid-19 pneumonia. [47] Moreover, indomethacin attenuated acute pancreatitis in mice through inhibition of NLRP3 inflammasome. [48] Thus, indomethacin might be effective for mild Covid-19 by its anti-inflammatory and antiviral activities, while abating the progression of cytokine storm through modulation the activity of NLRP3 inflammasome. [49, 50] However, omega-3 fatty acids have anti-inflammatory activities through inhibition of NLRP3 inflammasome and subsequent reduction in the release of IL-1β and caspase-1 activation. The omega-3 fatty acids is mediated by down-streaming of scaffold protein β-arrestin-2 in mice. [51] Weil et al., [52] , illustrated that the beneficial effect of omega-3 fatty acids against SARS-CoV-2 infection induced-inflammatory changes is mediated through reduction in the activity of NLRP3 inflammasome. However, prolong uses of omega-3 fatty acids makes the cell membrane vulnerable and susceptible to ROS and other free radicals that may increase the risk of paradoxical oxidative stress, which is a component in the origin and development of SARS-CoV-2 infection. [53] Glyburide is an oral hypoglycemic drug from sulfonylurea group and it has been widely used in managing type 2 diabetes mellitus (T2DM). [54] Glyburide inhibits the activation of NLRP3 inflammasome and IL-1β release in RNA virus infected cells. [55] Besides, metformin a first-line drug in the management of T2DM, acts through activation of AMP-activated protein kinase (AMPK) and blocking of mitochondrial complex I. [56] Metformin inhibits NLRP3 inflammasome through AMPK activation and autophagy with mTOR pathway inhibition in dilated cardiomyopathy. Also, metformin block caspase-1 and GSDMD-N that correlate with the NLRP3 inflammasome activation. [57] Different studies reported the beneficial effect of metformin therapy against SARS-CoV-2 infection by inhibiting viral replication, ACE2 phosphorylation dependent-inhibition of viral entry and amelioration of associated cytokine activation. [58, 59] In addition, pioglitazone, a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist ameliorated diabetic nephropathy through inhibition of NLRP3 inflammasome. [60] Pioglitazone and other PPAR-γ agonists may have potential role in the management of Covid-19-associated cytokine storm through inhibition of pro-inflammatory cytokines synthesis, NF-κB signaling and NLRP3 inflammasome. [61] Furthermore, a NF-κB signaling inhibitor tranilast is an effective anti-inflammatory drug used in the management of asthma. Tranilast prevents the assembly and activation of NLRP3 inflammasome as well as inhibition of the release of pro-inflammatory cytokines. [62] A review study reveal that tranilast may reduce Covid-19 severity during clinical trials. [63] Colchicine which is an alkaloid derivative drug has a marked anti-inflammatory effect by inhibiting NLRP3 inflammasome, neutrophil recruitments and adhesion molecules. Colchicine is widely used in the management of acute gout, familial meditation fever, pericarditis and other inflammatory disorders. [64] In Covid-19, high neutrophil recruitment is correlated with disease severity; thereby colchicine may reduce Covid-19 severity through inhibition of NLRP3 inflammasome, neutrophil recruitments, adhesion molecules and release of pro-inflammatory cytokines. [65] Polyphenolic resveratrol indirectly inhibits NLRP3 inflammasome, through suppression of mitochondrial damage and induction of autophagy. [66] Thus, resveratrol may serve as adjuvant therapy in severe Covid-19 patients via mitigation of NLRP3 inflammasome inducedinflammation and augmentation of cell autophagy. [67] In addition, resveratrol upregulates the expression of ACE2 receptors with significant inhibition of pro-inflammatory cytokines. [68] Lipid-lowering drugs may affect NLRP3 inflammasome activity and decrease complications related to inflammatory disorders regardless of lipid profile. Parsamanesh et al., [69] found that statins have anti-inflammatory and immunomodulatory effects through a regulation of the activity of NLRP3 inflammasome. Statins regulate the molecular platform of lysosomal function, ATP signaling, cathepsin-B, and K + ion efflux that contribute in the NLRP3 inflammasome activation. Notably, in vitro studies revealed that statins inhibit NLRP3 inflammasome activity due to atherogenic stimuli through blocking of pregnane x receptors (PXR). [70] However, separate studies reported that statins therapy is linked with NLRP3 inflammasome activation, caspase-1, IL-1β release that collectively contribute to the induction of T2DM. [71] Koushki et al., [72] demonstrated that statins may exert stimulatory or inhibitory effect on the NLRP3 inflammasome depending on their chemical structure and pharmacokinetic profile. Lipophilic statins like atorvastatin and simvastatin exert more effect on the TLR4/MYD88/NF-κB signaling and NLRP3 inflammasome compared with hydrophilic statins like rousovastatin. Therefore, all statins inhibit the activity of NLRP3 inflammasome except of simvastatin which might have a stimulatory effect on NLRP3 INFs.

Furthermore, a systematic review on statins usage in Covid-19 patients showed that the drug use is correlated with reduced death rate and severe cases in Covid-19 patients by 30%. Therefore, statins therapy is suggested to be effective therapy against moderate-severe Covid-19. [73] Therefore, NLRP3 inflammasome inhibitors play essential role in mitigation of immuneoveraction and hypercytokinemia in Covid-19 (Table 1) .

This work received no external funding

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 

Cold Spring Harbor perspectives in biology

Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases. Immunological reviews

Pattern recognition receptors and autophagy. Frontiers in Immunology

An update on PYRIN domain-containing pattern recognition receptors: from immunity to pathology. Frontiers in immunology

Inflammasomes: caspase-1-activating platforms with critical roles in host defense. Frontiers in microbiology

Inflammatory response in relation to COVID-19 and other prothrombotic phenotypes. Reumatología Clínica (English Edition)

Bacterial exotoxins and the inflammasome

Frequency of Interleukins IL1ß/IL18 and Inflammasome NLRP1/NLRP3 Polymorphisms in Sickle Cell Anemia Patients and their Association with Severity Score

Molecular mechanism of NLRP3 inflammasome activation

Uric acid as a danger signal in gout and its comorbidities

NLRP3 inflammasome pathways in atherosclerosis

López-Vales R. Olt1177 (dapansutrile), a selective nlrp3 inflammasome inhibitor, ameliorates experimental autoimmune encephalomyelitis pathogenesis

NLRP3 inflammasome and caspase-1/11 pathway orchestrate different outcomes in the host protection against Trypanosoma cruzi acute infection

The mitochondrial protease HtrA2 restricts the NLRP3 and AIM2 inflammasomes

Intracellular sensing of microbes and danger signals by the inflammasomes. Immunological reviews

Adiponectin Inhibits NLRP3 Inflammasome Activation in Nonalcoholic Steatohepatitis via AMPK-JNK/ErK1/2-NFκB/ROS Signaling Pathways. Frontiers in Medicine

Outer membrane vesicles prime and activate macrophage inflammasomes and cytokine secretion in vitro and in vivo

ZBP1 and TAK1: master regulators of NLRP3 inflammasome/pyroptosis, apoptosis, and necroptosis (PAN-optosis). Frontiers in cellular and infection microbiology

COVID-19 and phosphodiesterase enzyme type 5 inhibitors

Renin-Angiotensin system and fibrinolytic pathway in COVID-19: One-way skepticism

COVID-19 pneumonia in an Iraqi pregnant woman with preterm delivery

Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy

Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. Cell discovery

Inflammasome activation and innate immunity in Alzheimer's disease. Brain pathology

Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome. Frontiers in microbiology

NLRP3 inflammasome activation contributes to VSMC phenotypic transformation and proliferation in hypertension. Cell death & disease

Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerging microbes & infections

Middle East respiratory syndrome novel corona (MERS-CoV) infection

IL-1β and IL-6 upregulation in children with H1N1 influenza virus infection. Mediators of inflammation

IL-1 receptor antagonist therapy mitigates placental dysfunction and perinatal injury following Zika virus infection

Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients

Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools

The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection

Weathering the cytokine storm in susceptible patients with severe SARS-CoV-2 infection. The Journal of Allergy and Clinical Immunology: In Practice

Innate immune evasion by SARS-CoV-2: Comparison with SARS-CoV. Reviews in medical virology

SARS-CoV-2-specific virulence factors in COVID-19

Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19

Genetic variation and alterations of genes involved in NFκB/TNFAIP3-and NLRP3-inflammasome signaling affect susceptibility and outcome of colorectal cancer

Development of small molecule inhibitors targeting NLRP3 inflammasome pathway for inflammatory diseases

Persistent viral RNA positivity during the recovery period of a patient with SARS-CoV-2 infection

NLRP3 Inflammasome-A key player in antiviral responses

Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome

Phytochemicals: Potential Therapeutic Interventions Against Coronavirus-Associated Lung Injury

Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer's disease in rodent models

Use of Mefenamic Acid as a Supportive Treatment of COVID-19: A Repurposing Drug

Aspirin alleviates endothelial gap junction dysfunction through inhibition of NLRP3 inflammasome activation in LPS-induced vascular injury

Aspirin use is associated with decreased mechanical ventilation, ICU admission, and in-hospital mortality in hospitalized patients with COVID-19

Indomethacin inhabits the NLRP3 inflammasome pathway and protects severe acute pancreatitis in mice. Biochemical and biophysical research communications

Low Dose Indomethacin in the Outpatient Treatment of COVID-19 in Kidney Transplant Recipients-A Case Series

A paradigm shift in the role of NSAIDs in COVID-19: new pathological mechanisms and potential treatment targets

Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation

May omega-3 fatty acid dietary supplementation help reduce severe complications in Covid-19 patients?

Potential benefits and risks of omega-3 fatty acids supplementation to patients with COVID-19. Free Radical Biology and Medicine

Sulfonylurea and neuroprotection: The bright side of the moon

NLRP3 inflammasome inhibitor glyburide expedites diabetic-induced impaired fracture healing

Metformin and/or vildagliptin mitigate type II diabetes mellitus induced-oxidative stress: The intriguing effect

Metformin inhibits the NLRP3 inflammasome via AMPK/mTOR-dependent effects in diabetic cardiomyopathy

Metformin and COVID-19: From cellular mechanisms to reduced mortality

Observational study of metformin and risk of mortality in patients hospitalized with Covid-19

Pioglitazone ameliorates glomerular NLRP3 inflammasome activation in apolipoprotein E knockout mice with diabetes mellitus. PLoS One

Can pioglitazone be potentially useful therapeutically in treating patients with covid-19?

Tranilast directly targets NLRP 3 to treat inflammasome-driven diseases

Ongoing clinical trials for the management of the COVID-19 pandemic

Efficacy and safety of low-dose colchicine after myocardial infarction

Colchicine as a possible therapeutic option in COVID-19 infection

Resveratrol ameliorates LPS-induced acute lung injury via NLRP3 inflammasome modulation

Resveratrol and Copper for treatment of severe COVID-19: an observational study (RESCU 002). medRxiv

An approach of fatty acids and resveratrol in the prevention of COVID-19 severity

NLRP3 inflammasome as a treatment target in atherosclerosis: A focus on statin therapy

Statins attenuate activation of the NLRP3 inflammasome by oxidized LDL or TNFα in vascular endothelial cells through a PXR-dependent mechanism

Is immunity a mechanism contributing to statin-induced diabetes?

Anti-inflammatory Action of Statins in Cardiovascular Disease: the Role of Inflammasome and Toll-Like Receptor Pathways. Clinical reviews in allergy & immunology

Meta-analysis of effect of statins in patients with COVID-19